SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue guidance, attributed to sustained demand for Amtagvi and Proleukin, is driving attention as traders view it as evidence of commercial growth and improving execution. The reaction is broadly bullish, though some question whether the update is already priced in and look to upcoming lung-cancer data as another catalyst.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQures additional 48-month AMT-130 data for Huntingtons disease is driving attention: cUHDRS slowing weakened versus the 36-month results and did not reach statistical significance, prompting a sharp selloff. Traders debate whether the longer-term results reflect patient dropouts and changes in the external comparator, while bulls argue the FDA-aligned 36-month data remains the basis for the accelerated-approval filing.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFA changes allowing VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricing are fueling concern that competition could weaken FICOs longstanding mortgage-scoring advantage and revenue. Traders are split between viewing the selloff as a lasting threat to the moat and calling it an overreaction, citing FICOs broader software business and continued growth.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment in Summit and clinical collaboration to test ivonescimab in gastrointestinal cancers are driving attention, with traders viewing the deal as financing relief and a strong vote of confidence. Some caution that it is not an acquisition and that the separate FDA decision remains uncertain, while others warn of a possible sell-the-news reaction.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop ultra-high-voltage silicon carbide devices and validate domestic manufacturing is driving attention. Bulls see the award as meaningful technology and government validation, while skeptics note it is a prototype program with no disclosed financial terms or clear near-term revenue; short-squeeze hopes and sell-the-news concerns add to the debate.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

A sharp rebound has fueled breakout chatter, with bullish traders pointing to Zebecs payroll and payments partnershipsincluding MoneyGramas support for its adoption story. Others remain skeptical about weak price follow-through and real-world usage, while speculation about a Robinhood tie-up is unconfirmed.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles new change-of-control severance policy has sparked buyout speculation, though traders disagree on whether it signals anything beyond routine executive protections and there is no confirmed deal. The discussion also reflects concern about the lack of a shipment or launch date for BlueBirds 1416 and uncertainty around BlueBird 11s deployment.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

AVAXs sharp rally and rising volume have revived breakout talk, with traders pointing to broader altcoin momentum and the tokenization/institutional-adoption narrative, including reported NYSE testing of Avalanche technology. Others doubt the move is supported by lasting demand and warn it could fade as a speculative pump.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix reported an 89% complete-response rate in the 45-patient NEXICART-2 update, with all 25 newer patients in complete response or MRD-negative and no relapses or neurotoxicity reported to date. Traders welcomed the clinical results but debated the concurrent registered offering and its potential dilution.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks Phase 3 DAYBREAK results for its experimental wet AMD treatments Zenkuda and KSI-501 are driving attention after both met primary endpoints, fueling a sharp rally and talk of a short squeeze. Traders are divided between optimism about the drugs potential and concerns about valuation, future financing and dilution, FDA approval, and competition from established treatments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Chain Bridge Bancorp, Inc. (CBNA) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Chain Bridge Bancorp, Inc. (CBNA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Chain Bridge Bancorp, Inc. (CBNA) Beats Q2 Earnings and Revenue Estimates

Chain Bridge Bancorp, Inc. (CBNA) delivered earnings and revenue surprises of +9.85% and +2.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Chain Bridge Bancorp, Inc. Reports Second Quarter 2026 Financial Results

Chain Bridge Bancorp, Inc. (NYSE: CBNA) (the Company), the holding company for Chain Bridge Bank, N.A. (the Bank), today announced financial results for the second quarter of 2026 and the six months ended June 30, 2026. Second Quarter 2026 Financial Highlights (Three Months Ended June 30, 2026...

Fulton Financial (FULT) Surpasses Q2 Earnings and Revenue Estimates

Fulton Financial (FULT) delivered earnings and revenue surprises of +13.21% and +1.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bridgewater (BWB) Lags Q2 Earnings Estimates

Bridgewater (BWB) delivered earnings and revenue surprises of -2.17% and +1.72%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Chain Bridge Bancorp, Inc. (CBNA): Can Its 8.5% Jump Turn into More Strength?

Chain Bridge Bancorp, Inc. (CBNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Chain Bridge Bancorp, Inc. (CBNA) Upgraded to Strong Buy: What Does It Mean for the Stock?

Chain Bridge Bancorp, Inc. (CBNA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Chain Bridge Bancorp (NYSE:CBNA) Given New $39.50 Price Target at Hovde Group

Hovde Group upped their price objective on shares of Chain Bridge Bancorp from $38.00 to $39.50 and gave the company a 'market perform' rating in a report on Monday...

Surging Earnings Estimates Signal Upside for Chain Bridge Bancorp, Inc. (CBNA) Stock

Chain Bridge Bancorp, Inc. (CBNA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Chain Bridge Bancorp, Inc. (CBNA) Upgraded to Strong Buy: Here's Why

Chain Bridge Bancorp, Inc. is a bank holding company, which engages in the provision of banking services through its subsidiary. Its services include commercial and personal banking such as deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody. The company was founded by Peter G. Fitzgerald on May 26, 2006 and is headquartered in McLean, VA.

Chain Bridge Bancorp Inc. - Ordinary Shares - Class A

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$47.48
Prev Close	$47.76
Open	$47.11
Dividend Yield	0.00%
50-Day Moving Average	$46.15
Beta	0.60
Avg. Volume	20,715.08
PE Ratio	11.70

52-Week High	$49.71
52-Week Low	$28.10
Market Capitalization	$311.79M
EPS (Annual)	$3.08
Price to Book	1.70
Revenue Per Employee	$644,630.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

CBNA Fundamentals